Not recruiting
Registered drug
Study on the Effects of Atacicept in Adults with IgA Nephropathy
Registered drug
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:Atacicept
- Sponsor:Vera Therapeutics Inc.
Back to FranceClinical trials in Clichy – page 270
3 418 clinical trials in Clichy, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in FranceEssaisCliniques.fr(opens in a new tab)Clichy at a glance
3 418
clinical trials
- Research sites1
Not recruiting
Non-small cell lung cancer
Not recruitingStudy Comparing Nivolumab with Ipilimumab or Nivolumab with Chemotherapy to Chemotherapy Alone in Patients with Early Stage Non-Small Cell Lung Cancer
Registered drugNo placebo
Study Comparing Nivolumab with Ipilimumab or Nivolumab with Chemotherapy to Chemotherapy Alone in Patients with Early Stage Non-Small Cell Lung Cancer
Registered drugNo placebo
- Disease:Non-small cell lung cancer
- Substances:CarboplatinCisplatin+8
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Carboplatin
- Sponsor:Bristol Myers Squibb International Corporation
Not recruiting
Pneumonia bacterial
Not recruitingStudy on the Effectiveness and Safety of Imipenem, Cilastatin, and XNW4107 for Adults with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia
Registered drugNo placebo
Study on the Effectiveness and Safety of Imipenem, Cilastatin, and XNW4107 for Adults with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia
Registered drugNo placebo
- Disease:Pneumonia bacterial
- Substances:CilastatinImipenem+1
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Cilastatin
- Sponsor:Evopoint Biosciences USA Inc.
Not recruiting
Breast cancer
Not recruitingStudy Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment
Registered drugNo placebo
Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment
Registered drugNo placebo
- Disease:Breast cancer
- Substances:FulvestrantVepdegestrant
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Fulvestrant
- Sponsor:Pfizer Inc.
Not recruiting
Congenital generalised lipodystrophy
Not recruitingStudy on Metreleptin for Children Under 6 with Generalized Lipodystrophy and Related Diabetes or High Triglycerides
Registered drugNo placebo
Study on Metreleptin for Children Under 6 with Generalized Lipodystrophy and Related Diabetes or High Triglycerides
Registered drugNo placebo
- Disease:Congenital generalised lipodystrophy
- Substances:Metreleptin
Countries:France
France- Participants:0–17 years
- Substances:Metreleptin
- Sponsor:Amryt Pharmaceuticals Designated Activity Company
Not recruiting
Amyotrophic lateral sclerosis
Not recruitingStudy on the Effect of Salbutamol on Walking Ability in Patients with ALS
Registered drug
Study on the Effect of Salbutamol on Walking Ability in Patients with ALS
Registered drug
- Disease:Amyotrophic lateral sclerosis
- Substances:Salbutamol Sulfate
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Salbutamol Sulfate
- Sponsor:Assistance Publique Hopitaux De Paris
Not recruiting
Malignant melanoma
Not recruitingStudy on Nivolumab for Preventing Melanoma Recurrence in Patients with Completely Removed Stage IIB/C Melanoma
Registered drug
Study on Nivolumab for Preventing Melanoma Recurrence in Patients with Completely Removed Stage IIB/C Melanoma
Registered drug
- Disease:Malignant melanoma
- Substances:Nivolumab
Countries:France
France- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Nivolumab
- Sponsor:Bristol-Myers Squibb Services Unlimited Company
Not recruiting
Hidradenitis
Not recruitingStudy on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa
Investigational
Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa
Investigational
- Disease:Hidradenitis
- Substances:Povorcitinib
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Povorcitinib
- Sponsor:Incyte Corp.
Not recruiting
Acute myeloid leukaemia
Not recruitingStudy on Azacitidine and Gilteritinib for Adults with Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
Registered drugNo placebo
Study on Azacitidine and Gilteritinib for Adults with Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
Registered drugNo placebo
- Disease:Acute myeloid leukaemia
- Substances:AzacitidineGilteritinib
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Azacitidine
- Sponsor:French Innovative Leukemia Organization
Not recruiting
Hidradenitis
Not recruitingStudy on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa
Investigational
Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa
Investigational
- Disease:Hidradenitis
- Substances:Povorcitinib
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Povorcitinib
- Sponsor:Incyte Corp.
Not recruiting
Dermatomyositis
Not recruitingStudy on the Effects of GLPG3667 for Adults with Dermatomyositis
Investigational
Study on the Effects of GLPG3667 for Adults with Dermatomyositis
Investigational
- Disease:Dermatomyositis
- Substances:–
Countries:France
France- Participants:18–64 years · 65+ years
- Sponsor:Galapagos
Not recruiting
Hormone receptor positive HER2 negative breast cancer
Not recruitingStudy of Capivasertib with CDK4/6 Inhibitors and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer
Registered drugNo placebo
Study of Capivasertib with CDK4/6 Inhibitors and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer
Registered drugNo placebo
- Disease:Hormone receptor positive HER2 negative breast cancer
- Substances:AbemaciclibCapivasertib+3
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Abemaciclib
- Sponsor:AstraZeneca AB
Other cities in France
The busiest research cities in the country
- Paris2 648 trials · 36 research sites
- Toulouse1 534 trials · 4 research sites
- Marseille1 508 trials · 7 research sites
- Lille1 352 trials · 3 research sites
- Lyon1 214 trials · 7 research sites
- Bordeaux1 178 trials · 2 research sites
- Montpellier1 117 trials · 4 research sites
- STRASBOURG, Alsace997 trials · 6 research sites
Clinical research in Clichy
What the registry says about research in the country
01 Gastrointestinal Disorders
Innovative trials focusing on inflammatory bowel diseases and advanced treatment methods, including studies on Crohn's disease and ulcerative colitis using fecal microbiota transplantation as therapeutic approaches.
- Crohn's Disease Management
- Ulcerative Colitis Treatment
- Short Bowel Syndrome
Research aims to improve patient outcomes through novel therapeutic interventions and treatment strategies.
02 Hepatobiliary Research
Comprehensive studies on liver diseases and biliary tract conditions, investigating new treatments for cirrhosis, portal hypertension, and various forms of liver cancer.
- Hepatocellular Carcinoma
- Biliary Tract Cancer
- Liver Cirrhosis
Advanced therapeutic approaches combining immunotherapy and targeted treatments.
03 Pancreatic and Metabolic Disorders
Groundbreaking research on pancreatic cancer and metabolic conditions, evaluating novel drug combinations and treatment protocols.
- Pancreatic Adenocarcinoma
- Neuroendocrine Tumors
- Metabolic Liver Disease
Focus on improving survival rates and treatment efficacy in advanced-stage diseases.